EGFR and non-small cell lung carcinoma: Advanced NSCLC patients bearing EGFR mutations only account for about 5-14% of the total number of patients recruited in the major clinical trials investigating the four approved anti-PD-1/PD-L1 ICIs (Table 1) (8, 9, 11, 25, 46, 51, 52).